Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics, Inc. has a significant shareholder group led by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, which jointly report beneficial ownership of 7,736,455 shares of common stock. This represents 7.45% of Nurix’s common stock outstanding as of June 30, 2026, based on 103,781,683 shares reported in the company’s 10-Q. The reporting persons hold no sole voting or dispositive power but have shared voting and shared dispositive power over all 7,736,455 shares, indicating coordinated control over how this block may be voted or sold.
Nurix Therapeutics, Inc. reported that Chief Scientific Officer Gwenn Hansen exercised employee stock options for 4,356 shares at an exercise price of $1.8600 per share and sold 4,356 common shares at $25.0000 per share on August 5, 2026 under a Rule 10b5-1 trading plan. After the exercise, 62,310 options from this grant remained outstanding, with an option expiration date of 2029-08-28.
A shareholder of NRIX, identified as Gwenn M. Hansen, filed to sell common stock, including 8,712 shares through Morgan Stanley Smith Barney LLC Executive Financial Services, tied to an exercise of stock options on 08/05/2026. The filing also lists several recent Rule 10b5-1 plan sales of common shares over the prior three months.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported selling a total of 4,111 shares of common stock on 2026-08-04 in two transactions at weighted average prices of $23.8684 and $24.6415. The sales were effected pursuant to a previously adopted Rule 10b5-1 trading plan.
Nurix Therapeutics, Inc. reported that Chief Financial Officer Hans van Houte sold a total of 4,761 shares of common stock on August 4, 2026, in two open-market or private transactions at weighted average prices of $23.8911 and $24.6474 per share pursuant to a previously adopted Rule 10b5-1 trading plan, with sale prices ranging between $23.42 and $24.83.
NRIX received a notice of proposed stock sales by an affiliate. The filing lists plans to sell 4,111 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, associated with restricted stock units dated July 30, 2026, on NASDAQ. It also notes prior Rule 10b5-1 sales for Gwenn M. Hansen totaling 5,394 common shares on June 25, 2026 for $107,880.00.
NRIX security holder Johannes Van Houte has filed to sell common stock under Rule 144. The filing lists 4,761 common shares to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate value of $110,550.42. These shares are tied to Restricted Stock Units dated July 30, 2026.
The filing also reports prior sales in the last three months: 2,845 common shares sold on July 30, 2026 for $66,524.07, and 14,055 common shares sold on May 5, 2026 for $233,319.27, identified as 10b5-1 sales for Johannes Van Houte.
Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised employee stock options for 5,787 shares of common stock at an exercise price of $8.72 per share and, on the same date, sold 16,589 common shares at a weighted average price of $23.0489 (within a $22.67–$23.30 range). Following the option exercise, 122,824 stock options tied to common stock remain outstanding, expiring in 2034. These transactions were effected under a previously adopted Rule 10b5-1 trading plan.
Nurix Therapeutics, Inc. (NRIX) reports that insider Christine Ring has filed to sell up to 16,589 shares of common stock, with an aggregate market value of $385,030.69, through Morgan Stanley Smith Barney LLC, with sales expected on or after August 3, 2026 on NASDAQ. The shares derive from an exercise of stock options for 5,787 shares on August 3, 2026 for cash and 10,802 restricted stock units vesting on July 30, 2025. The filing also lists prior Rule 10b5-1 sales over the past three months, including a sale of 28,935 shares for $580,506.12 on June 25, 2026, along with several smaller transactions.
Vanguard Capital Management LLC and certain affiliates report beneficial ownership of 5,202,025 shares of Nurix Therapeutics Inc. common stock, representing 5.03% of the class as of June 30, 2026.
Vanguard has sole voting power over 706,496 shares and sole dispositive power over all 5,202,025 shares, with no shared voting or dispositive power. The position reflects securities held by Vanguard funds and managed accounts over which Vanguard entities exercise voting and/or dispositive authority, and no other individual person's interest exceeds 5% of the class.